Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s share price traded down 3.8% during trading on Friday following a weaker than expected earnings announcement. The company traded as low as $6.61 and last traded at $7.38. 19,725,110 shares were traded during trading, a decline of 23% from the average session volume of 25,633,920 shares. The stock had previously closed at $7.67.
The company reported ($0.53) EPS for the quarter, missing the consensus estimate of ($0.36) by ($0.17). Recursion Pharmaceuticals had a negative return on equity of 76.56% and a negative net margin of 579.52%. The business had revenue of $4.60 million during the quarter, compared to the consensus estimate of $19.04 million. During the same period last year, the business posted ($0.42) earnings per share. The firm’s quarterly revenue was down 57.8% on a year-over-year basis.
Wall Street Analysts Forecast Growth
A number of brokerages have issued reports on RXRX. KeyCorp cut their price objective on shares of Recursion Pharmaceuticals from $12.00 to $10.00 and set an “overweight” rating for the company in a report on Wednesday, January 8th. Needham & Company LLC reissued a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Thursday, February 6th.
Institutional Trading of Recursion Pharmaceuticals
A number of hedge funds have recently made changes to their positions in RXRX. Allspring Global Investments Holdings LLC acquired a new stake in Recursion Pharmaceuticals during the 3rd quarter worth about $25,000. Decker Retirement Planning Inc. acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at approximately $26,000. Private Trust Co. NA bought a new stake in shares of Recursion Pharmaceuticals in the fourth quarter valued at about $27,000. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 1,979.2% in the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company’s stock valued at $35,000 after buying an additional 4,948 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its holdings in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company’s stock worth $42,000 after buying an additional 4,091 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company’s stock.
Recursion Pharmaceuticals Stock Down 3.7 %
The stock has a market capitalization of $2.88 billion, a P/E ratio of -4.82 and a beta of 0.86. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The firm has a 50 day simple moving average of $7.69 and a two-hundred day simple moving average of $7.07.
About Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Featured Stories
- Five stocks we like better than Recursion Pharmaceuticals
- Why Are These Companies Considered Blue Chips?
- 5 Best Gold ETFs for March to Curb Recession Fears
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- 3 Stocks for Your Watchlist: Unlocking Tomorrow’s Winners Today
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Why Smart Investors Are Watching These 3 Undervalued Stocks
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.